Parikh SV, et al.. Update on lupus nephritis: Core curriculum 2020. Am J Kidney Dis 2020; 76:265−281. doi: 10.1053/j.ajkd.2019.10.017
Furie R, et al.. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 2020; 383:1117−1128. doi: 0.1056/NEJMoa2001180
Atisha-Fregoso Y, et al.. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol [published online ahead of print August 4, 2020]. doi: 10.1002/art.41466; https://onlinelibrary.wiley.com/doi/10.1002/art.41466
Furie R, et al.. A phase II randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of obinutuzumab or placebo in combination with mycophenolate mofetil in patients with active class III or IV lupus nephritis (abstract). Arthritis Rheumatol 2019; 71 (Suppl 10):939. https://acrabstracts.org/abstract/a-phase-ii-randomized-double-blind-placebo-controlled-study-to-evaluate-the-efficacy-and-safety-of-obinutuzumab-or-placebo-in-combination-with-mycophenolate-mofetil-in-patients-with-active-class-iii/
Rovin BH, et al.. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int 2019; 95:219−231. doi: 10.1016/j.kint.2018.08.025
Arriens C, et al.. AURORA phase 3 study demonstrates voclosporin statistical superiority over standard of care in lupus nephritis. Aurinia. June 5, 2020. https://d1io3yog0oux5.cloudfront.net/_b9287cb2b9b32ac3fbb5d08113841567/auriniapharma/db/246/1327/pdf/EULAR+2020+AURORA_Presentation+Deck+05Jun2020.pdf
Aurinia. FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis. January 22, 2021. https://ir.auriniapharma.com/press-releases/detail/210
MetroHealth Medical Center. Pentoxifylline in Lupus Nephritis (Pentoxifylline). ClinicalTrials.gov: NCT03859570. https://clinicaltrials.gov/ct2/show/NCT03859570
BeiGene. Zanubrutinib in Participants with Active Proliferative Lupus Nephritis. ClinicalTrials.gov: NCT04643470. https://clinicaltrials.gov/ct2/show/NCT04643470
Janssen Research & Development, LLC. A Study of Guselkumab in Participants with Active Lupus Nephritis (ORCHID-LN). ClinicalTrials.gov: NCT04376827. https://clinicaltrials.gov/ct2/show/NCT04376827